Search stocks

Find any stock by ticker or company name

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Watchlist
Markets
Calendar
Screener
News
About

Home

/

REVB

R

Revelation Biosciences, Inc. (REVB)

NCM – Real Time Price. Currency in USD

1.11

-0.02 (-1.77%)

Market open: Aug 12, 2026, 11:10 AM EDT

1.08

-0.05 (-4.42%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and six months ended June 30, 2026. Corporate Highlights Announced formation of an Acute Kidney Injury Advisory Board for the upcoming Phase 2/3 AKI clinical trial and subsequent expansion of the AKI Advisory Board Continued progress on Phase 2/3 clinical study start up activities Released results of an independent market assessment that showed a potential $94 billion total addressable market for Gemini "Start-up activities for our pivotal clinical study of Gemini in acute kidney injury patients continue to progress," said James Rolke, Chief Executive Officer of Revelation.

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today results of an independent market assessment which identified a potential $94 billion total addressable market for Gemini, confirming the unmet medical need. The independent market assessment evaluated Gemini for the treatment of Stage 2 and Stage 3 Acute Kidney Injury (AKI), a major cause of morbidity and mortality, which according to publicly available data affects more than 10% of all hospitalized patients and more than 50% of patients admitted to intensive care units (ICUs).

Videos

No Data

There is no data to display

Press releases

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and six months ended June 30, 2026. Corporate Highlights Announced formation of an Acute Kidney Injury Advisory Board for the upcoming Phase 2/3 AKI clinical trial and subsequent expansion of the AKI Advisory Board Continued progress on Phase 2/3 clinical study start up activities Released results of an independent market assessment that showed a potential $94 billion total addressable market for Gemini "Start-up activities for our pivotal clinical study of Gemini in acute kidney injury patients continue to progress," said James Rolke, Chief Executive Officer of Revelation.

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today results of an independent market assessment which identified a potential $94 billion total addressable market for Gemini, confirming the unmet medical need. The independent market assessment evaluated Gemini for the treatment of Stage 2 and Stage 3 Acute Kidney Injury (AKI), a major cause of morbidity and mortality, which according to publicly available data affects more than 10% of all hospitalized patients and more than 50% of patients admitted to intensive care units (ICUs).